News headlines about Catalent (NYSE:CTLT) have trended somewhat positive on Monday, Accern reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Catalent earned a news impact score of 0.14 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.4344539741612 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the headlines that may have effected Accern’s scoring:

A number of equities analysts have recently weighed in on the company. Royal Bank of Canada set a $48.00 target price on Catalent and gave the stock a “buy” rating in a research note on Monday, February 5th. Stephens lowered Catalent from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, February 6th. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th. Zacks Investment Research upgraded Catalent from a “hold” rating to a “buy” rating and set a $48.00 target price on the stock in a research note on Monday, November 6th. Finally, BidaskClub lowered Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Catalent currently has a consensus rating of “Buy” and an average price target of $45.60.

Catalent (NYSE:CTLT) traded up $0.50 during trading on Monday, reaching $43.37. The company’s stock had a trading volume of 772,700 shares, compared to its average volume of 1,011,991. Catalent has a 12-month low of $27.48 and a 12-month high of $47.87. The company has a debt-to-equity ratio of 2.66, a quick ratio of 1.78 and a current ratio of 2.22. The company has a market cap of $5,760.00, a price-to-earnings ratio of 78.85, a PEG ratio of 2.49 and a beta of 1.47.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Monday, February 5th. The company reported $0.41 EPS for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.10. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The firm had revenue of $606.30 million for the quarter, compared to analyst estimates of $565.05 million. During the same quarter last year, the company earned $0.27 EPS. The company’s revenue was up 25.3% on a year-over-year basis. equities analysts expect that Catalent will post 1.53 earnings per share for the current year.

In related news, Director Uwe Roehrhoff acquired 7,500 shares of the stock in a transaction on Tuesday, November 21st. The shares were purchased at an average price of $39.22 per share, for a total transaction of $294,150.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Catalent (CTLT) Earns Daily News Sentiment Score of 0.14” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Insider Buying and Selling by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with's FREE daily email newsletter.